Blocking endothelin to improve blood vessel function in large vessel vasculitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of Bosentan, a dual endothelin receptor antagonist, on blood vessel function in patients with large vessel vasculitis (LVV) who have been in remission for at least six months. Initially, the study will compare endothelial function between LVV patients and matched controls without the condition. Following this, LVV participants will receive Bosentan for six weeks to evaluate its impact on their vascular health. The primary assessment method will be forearm plethysmography, which is considered the gold standard for measuring endothelial function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A diagnosis of large vessel vasculitis that has been in remission for ≥ 6 months.

Exclusion Criteria:

* Age \<18 years
* Active LVV
* Any organ transplant recipients
* A requirement for any medications that are contra-indicated whilst taking Bosentan or dapagliflozin
* Congestive cardiac failure
* Patients not medically fit to attend study visits
* Patients without mental capacity or willingness to provide informed consent
* History of multiple and/or severe (clinical judgement as determined by the Investigator) allergic reactions to drugs, including the study drug, or food
* Patients who are pregnant or breast feeding, or those who plan to become pregnant during the study
* Participation in another clinical trial for 28 days before or 90 days after the study period

Where it's running

• University of Edinburgh
  Edinburgh, United Kingdom Recruiting

Study contacts

• Study coordinator: Alex Armstrong
• Email: a.armstrong-9@sms.ed.ac.uk
• Phone: +447445695898

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Giant Cell Arteritis: Monitoring Disease Activity and Relapse Risk in Remission

  This study tests tools that help monitor disease activity and predict relapses in people with giant cell arteritis who are in remission.

  Recruiting at 4 sites University of Aarhus · Aalborg and 6 other locations · NCT07552636

• Stopping biologic therapy in Takayasu arteritis patients in long-term remission

  This study will try stopping biologic medicines (TNF inhibitors or tocilizumab) in people with Takayasu arteritis who have been in clinical and imaging remission for at least three years to see if remission lasts for 12 months.

  Recruiting Marmara University · Istanbul · NCT07491913

• Understanding patient and physician experiences and attitudes toward care in Takayasu arteritis.

  This project asks adults with Takayasu arteritis and the doctors who treat them to complete online questionnaires to see what their experiences and care priorities are.

  Recruiting University of Edinburgh · Edinburgh · NCT07351422

• Comparing physical and psychosocial health in people with Takayasu arteritis, Behçet's disease, and healthy adults

  This will test whether adults with Takayasu arteritis or Behçet's disease have weaker respiratory and limb muscles, lower exercise capacity, or different quality of life and psychological well‑being compared with healthy adults.

  Recruiting Alanya Alaaddin Keykubat University · Denizli, Denizli · NCT07276087

• Combining vascular ultrasound and blood markers to improve diagnosis and monitoring of giant cell arteritis

  This project will test whether adding extended ultrasound scans to new blood biomarkers can better predict relapse and tell active from inactive giant cell arteritis in people referred for suspected GCA.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT07246577

• Orbital blood-vessel inflammation in giant cell arteritis and ischemic optic neuropathy

  This project will test whether advanced FDG PET/MRI with black-blood sequences plus OCT scans can tell if sudden optic nerve damage is due to giant cell arteritis or non-arteritic ischemic optic neuropathy in people aged 50 and older.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Glostrup Municipality · NCT07206238

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.